2,3-O-(isopropylidene)-4,5-O-sulfonyl-β-D-fructopyranose | 82944-96-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧吡喃
• 英文名称: 2,3-O-(isopropylidene)-4,5-O-sulfonyl-β-D-fructopyranose
• 英文别名: 2,3-O-isopropylidene-β-D-fructopyranose 4,5-cyclic sulfate；[(1S,2S,6R,9S)-11,11-dimethyl-4,4-dioxo-3,5,8,10,12-pentaoxa-4lambda6-thiatricyclo[7.3.0.02,6]dodecan-9-yl]methanol；[(1S,2S,6R,9S)-11,11-dimethyl-4,4-dioxo-3,5,8,10,12-pentaoxa-4λ6-thiatricyclo[7.3.0.02,6]dodecan-9-yl]methanol
• CAS: 82944-96-5
• 化学式: C₉H₁₄O₈S
• 分子量: 282.271
• InChiKey: LNMPNVPDAGUEAI-JAKMQLQISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2,3-O-(isopropylidene)-4,5-O-sulfonyl-β-D-fructopyranose 在 palladium on activated charcoal 吡啶 、 sodium azide 、 氢气 、 磺酰胺 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， -20.0~23.0 ℃ 、289.58 kPa 条件下， 反应 50.5h， 生成 (1S,2S,6R,9S)-11,11-dimethyl-4,4-dioxo-9-[(sulfamoylamino)methyl]-3,5,8,10,12-pentaoxa-4lambda6-thiatricyclo[7.3.0.02,6]dodecane
  参考文献：
  名称：

  Comparison of Sulfamate and Sulfamide Groups for the Inhibition of Carbonic Anhydrase-II by Using Topiramate as a Structural Platform

  摘要：

  This paper examines the relative effectiveness of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II (CA-H). Topiramate (1) and its sulfamide analogue 4, and 4,5-cyclic sulfate 6 and its sulfamide analogue 5, were compared for inhibition of human CA-II. A colorimetric assay, based on the pH shift that accompanies hydration of carbon dioxide, and an esterase assay were used. For these bioisosteric pairs, 1/4 and 6/5, the sulfamate compound was markedly more potent than its sulfamide counterpart. A similar, large difference in potency was also observed for the sulfamate/sulfamide pairs 14/15 and 16/17. These results indicate that the sulfamide moiety is not particularly suitable for obtaining potent carbonic anhydrase inhibition. A discussion of this structure-activity relationship with respect to the interactions of 1 and 6 with CA-H from published X-ray data is presented. A metabolic acidosis study was performed in rats with 1, 4, 6, and 2, and the results are discussed with respect to the degree of inhibition of CA-II in vivo.

  DOI：

  10.1021/jm040124c
• 作为产物：
  描述：

  果糖二丙酮 在 吡啶 、 磺酰氯 、 Dowex 50W-X₈ (H+) resin 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 146.0h， 生成 2,3-O-(isopropylidene)-4,5-O-sulfonyl-β-D-fructopyranose
  参考文献：
  名称：

  Structure–sweetness relationships for fructose analogs. Part I. Synthesis and evaluation of sweetness of 5-deoxy-D-threo-hexulose

  摘要：

  5-去氧-D-己糖（“5-去氧果糖”，“5-去氧山梨糖”）已从D-果糖经过六步制备。2,3-O-异丙基醚基-β-D-果糖吡喃糖与亚磺酰氯反应的关键步骤中，仅产生5-氯-5-去氧-2,3-O-异丙基醚基-α-L-山梨糖吡喃糖。在溶液中，“5-去氧果糖”仅以²C₅(D)吡喃状形式存在，并被发现比L-山梨糖甜得多，几乎与D-果糖一样甜。对这种意外的甜味结果进行了评论。

  DOI：

  10.1139/v82-258

文献信息

• Structure−Activity Studies on Anticonvulsant Sugar Sulfamates Related to Topiramate. Enhanced Potency with Cyclic Sulfate Derivatives
  作者：Bruce E. Maryanoff、Michael J. Costanzo、Samuel O. Nortey、Michael N. Greco、Richard P. Shank、James J. Schupsky、Marta P. Ortegon、Jeffry L. Vaught

  DOI：10.1021/jm970790w

  日期：1998.4.1

  22-25, 27, 84), (2) the linker between the sulfamate group and the pyran ring (9, 10, 21a,b), (3) the substituents on the 2,3- (58-60, 85, 86) and 4, 5-fused (30-38, 43, 45-47, 52, 53) 1,3-dioxolane rings, (4) the constitution of the 4,5-fused 1,3-dioxolane ring (2, 54, 55, 63-68, 76, 77, 80, 83a-r, 84-87, 90a, 91a, 93a), (5) the ring oxygen atoms (95, 96, 100-102, 104, 105), and (6) the absolute stereochemistry

  我们已经探索了围绕临床有效的抗癫痫药托吡酯（1）的结构-活性关系（SAR），这是在我们的实验室中发现的一种独特的糖氨基磺酸盐类抗惊厥药。母体化合物的系统结构修饰旨在鉴定具有长效作用时间和良好神经毒性指数的有效抗惊厥药。在此背景下，我们探讨了几种分子特征的药理重要性：（1）氨基磺酸酯基团（6-8、22-25、27、84），（2）氨基磺酸酯基团与吡喃环之间的连接子（9） ，10、21a，b），（3）2,3-（58-60、85、86）和4,5-稠合（30-38、43、45-47、52、53）1上的取代基，3-二氧戊环，（4）4,5-稠合的1,3-二氧戊环的结构（2，54，55，63-68，76，77，80，83a-r，84-87，90a ，91a，93a），（5）环氧原子（95、96、100-102、104、105），和（6）绝对立体化学（106和107）。通过对氨基磺酸氨基甲酸酯21a的主要非
• Use of sulfamate derivatives for treating impulse control disorders
  申请人：——

  公开号：US20010023254A1

  公开（公告）日：2001-09-20

  Impulse Control Disorders (ICD's) are characterized by harmful behaviors performed in response to irresistible impulses. The essential feature of an ICD is the failure to resist an impulse, drive, or temptation and to perform an act that is harmful to the person or to others. The present invention comprises methods for the treatment or prevention of ICD's using a class of sulfamates of the following formula: 1 wherein X is CH 2 or oxygen, and R 1 , R 2 , R 3 , R4 and R 5 are as herein defined. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention are also disclosed.

  冲动控制障碍(ICD)的特征为在无法抵制的冲动下进行有害行为。ICD的本质特征是无法抵制冲动、驱动力或诱惑，并执行对个人或他人有害的行为。本发明涉及使用以下公式的磺酰胺类治疗或预防ICD的方法：1其中X为CH2或氧，R1、R2、R3、R4和R5如本文所定义。此外，本发明还揭示了含有公式(I)化合物的制药组合物以及其使用方法和中间体。
• Anticonvulsant fructopyranose cyclic sulfites and sulfates
  申请人：MCNEILAB, INC.

  公开号：EP0568306A1

  公开（公告）日：1993-11-03

  Compounds of the general formula (I): wherein R₁, R₂, R₃, R₄, R₅, R₆, n and p are as herein defined; exhibit anticonvulsant activity and are thus useful in the treatment of conditions such as epilepsy. Compounds of this class are also useful for the treatment of glaucoma and peptic ulcers. Furthermore, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and novel intermediates are disclosed.

  通式 (I) 的化合物： 其中 R₁、R₂、R₃、R₄、R₅、R₆、n 和 p 如本文所定义；具有抗惊厥活性，因此可用于治疗癫痫等疾病。该类化合物还可用于治疗青光眼和消化性溃疡。此外，还公开了含有式（I）化合物的药物组合物及其使用方法和新型中间体。
• Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
  申请人：MCNEILAB, INC.

  公开号：EP0574256A1

  公开（公告）日：1993-12-15

  Imidate derivatives of sulfamates having the following formula (I): wherein R₁, R₂, R₃, R₄ and X are as herein defined have been found to be useful prodrug and exhibit anticonvulsant activity when converted to the active agent upon administration to a mammal and are thus useful in the treatment of conditions such as epilepsy. Further, the present invention encompasses pharmaceutical compositions containing a compound of formula (I) as well as methods for their use.

  具有下式 (I) 的氨基磺酸亚胺酯衍生物： 其中 R₁、R₂、R₃、R₄ 和 X 如本文所定义，已被发现是有用的原药，在给哺乳动物用药后转化为活性剂时表现出抗惊厥活性，因此可用于治疗癫痫等疾病。此外，本发明还包括含有式（I）化合物的药物组合物及其使用方法。
• USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS
  申请人：UNIVERSITY OF CINCINNATI

  公开号：EP1158973B1

  公开（公告）日：2005-05-04